Mill Capital Management LLC Purchases New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Mill Capital Management LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,384 shares of the medical equipment provider’s stock, valued at approximately $464,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ZBH. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the 4th quarter valued at about $204,000. Sivia Capital Partners LLC bought a new stake in Zimmer Biomet during the second quarter worth approximately $232,000. United Bank raised its position in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after purchasing an additional 1,153 shares during the period. Federated Hermes Inc. raised its position in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZBH shares. JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Citizens Jmp decreased their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a report on Wednesday, April 29th. Barclays lowered their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. UBS Group reaffirmed a “buy” rating and set a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, Zacks Research cut shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $104.42.

Insiders Place Their Bets

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Trading Up 1.0%

ZBH opened at $100.52 on Friday. The stock has a market cap of $19.17 billion, a price-to-earnings ratio of 24.46, a P/E/G ratio of 3.17 and a beta of 0.45. The stock’s 50 day moving average price is $91.51 and its 200-day moving average price is $90.54. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the business posted $2.07 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were paid a $0.24 dividend. The ex-dividend date was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.